loader2
Login Open ICICI 3-in-1 Account
  • CMP : 706.0 Chg : 7.25 (1.04%)
  • Target : 340.0 (21.43%)
  • Target Period : 12-18 Month

27 May 2022

Footfall consistency buoys operational metrics…

About The Stock

HCG operates one of the largest private cancer care networks in India with end-to-end solutions available under a single corporate entity. Most centres are on a lease or rental basis with some in partnership with local doctors or hospitals. Owing to exclusive agreement with vendors, HCG procures equipment on a deferred payment basis. Milann offers seven fertility centres in India.

  • HCG network has 22 comprehensive cancer centres (one in Kenya, four multi-specialty hospitals. HCG India, capacity beds: 1944; 1702 operational
  • Revenue mix FY22: HCG: 96%, Milann:4%; occupancy FY22: 58.3%; ARPOBD FY22: 36,697
Q4FY22

HCG reported continued momentum this quarter.

  • Sales were up 22% YoY to ₹ 365 crore
  • EBITDA was at ₹ 63 crore, up 57% YoY with margins at 17.3%
  • Consequent adjusted profit for the quarter was at ₹ 6 crore
What should Investors do?

HCG’s share price has grown by ~1.1x over the past five years (from ~₹ 245 in May 2017 to ~₹ 280 in May 2022).

  • Upgrade from HOLD to BUY on 1) consistency in footfalls likely to continue in normalised FY23, 2) newer assets to turn profitable, complement existing centres, 3) singular focus to consolidate existing business
Target Price Valuation

We value HCG at ₹ 340 (HCG centres at 14x FY24E EV/EBITDA and Milann centres at 1x FY24E EV/sales).

Key Triggers for future price performance
  • HCG, with its integrated, one-stop-solution and focused model, is well poised to capture growing potential with pan-India focus on cancer therapy
  • Focused on consolidating existing network through cost optimisation measures to improve margin and ramping up patient’s footfall by engaging in direct-to patient promotion strategies
  • Oncology cases are expected to increase by 100k to 350k cases a year which bodes well for HCG with hybrid presence (Metros/Tier-II, III towns)
  • De-leveraging of balance sheet, reduction of losses across new centres have substantially eased legacy overhangs. improvement in consolidated return ratio profile still remains a key
New Stock Ideas

Apart from HCG, in our hospital coverage we like Narayana.

  • Narayana operates a duel model, which perfectly blends established ‘’Assetright’’ India business with a hospital in Cayman Islands
  • BUY with a target price of ₹ 750

Key Financial Summary

Particulars FY19 FY20 FY21 FY22 5 Year CAGR(FY17-FY22) FY23E FY24E 2 Year CAGR (FY22-FY24E)
Revenues 976.0 1,095.6 1,013.4 1,397.8 14.8 1,549.0 1,708.2 10.5
EBITDA 111.6 159.9 126.2 236.5 17.6 279.5 329.1 17.9
EBITDA margins (%) 11.4 14.6 12.5 16.9 - 18.0 19.3 -
Net Profit -30.9 -125.4 -193.5 53.7 19.4 50.3 111.7 44.2
EPS (|) -2.8 -12.0 -11.2 -2.9 - 3.6 8.0 -
M.Cap/ Revenues (x) 2.4 2.1 2.3 2.8 - 2.5 2.3 -
EV to EBITDA (x) 26.8 22.9 26.0 19.5 - 16.0 12.9 -
RoCE (%) 3.0 1.0 -0.9 5.0 - 7.6 10.2 -
Source: Company, ICICI Direct Research

Key takeaways of recent quarter & conference call highlights

Q4FY22 Results: Robust performance continues

  • Healthcare Global’s (HCG) revenues grew 22% YoY to | 365 crore driven by 23% YoY growth in HCG centres and 12% YoY growth in Milann centres. EBITDA margins improved 382 bps YoY to 17.3% while EBITDA grew 57% YoY to | 63 crore. Adjusted net profit for the quarter was at | 6 crore against loss of | 10 crore in Q4FY21
  • HCG posted good numbers in Q4 in-line with our estimates. Amid strong yearly growth in footfalls and several centres witnessing turnaround in EBITDA. HCG ended FY22 with, operating EBITDA margins of 21.5% vs. 17.4% in FY21 for existing centres and operating EBITDA of | 7.2 crore for new centres vs. loss of | 15.7 crore in FY21. HCG, with its integrated, one-stop-solution and focused model, is well poised to capture the growing potential with pan- India focus on cancer therapy. HCG is now looking to be in a consolidation mode and improve its weaker return ratio profile, going ahead

Q4FY22 Earnings Conference Call highlights

  • In Q4FY22, there was a one-time project fee of | 2.5 crore for FY22. As a whole. the amount was |4.5 crore and DTA recognised on tax expense through the year, on account of discontinuance of Kochi project | 2.5 crore
  • Revenue split geographically is Karnataka 36%, Gujarat 26%, Maharashtra 17%, East India 9%, AP 8%, Tamil Nadu 2%, North India 3%.
  • Occupancy levels for FY22 were 58.3% vs. 48.4% in FY21. For existing centres occupancy level for Q4FY22 was 59.1% vs. 55.5% in Q4FY21
  • ALOS for FY22 was 2.28 days compared to 2.29 days in FY21
  • ARPOB for FY22 was | 36697 compared to | 32632 in FY21. For existing centres ARPOB was | 38200 (including vaccination business) for FY22 and | 39725 for Q4FY22 (11.8% YoY growth)
  • EBITDA margins geography wise were Karnataka 23.8%, Gujarat 21.8%, Maharashtra 15.2%, East India 11.5%, AP 21.6%
  • Total capex for FY22 was | 70.4 crore while net debt for FY22 was at | 697.2 crore (including leases)
  • Bangalore centres have an RoCE of 25-26% while for Ahmedabad centres it was ~30% and RoCE for mature centres will be in higher teens
  • Bangalore and Ahmedabad have higher ARPOB compared to others. Kolkata and Mumbai are also expected to go forward in a similar direction
  • In Ahmedabad HCG will have a dedicated cancer centre (Phase 2). The work has commenced there. No other greenfield projects are planned
  • ALOS will come down as and when HCG shifts to robotics in their operations
  • In March, the company recorded international business at above pre-Covid levels, which amounted to ~4% of the topline and is expected to continue. In Mumbai, international business is growing quickly
  • In mature centres HCG is focusing not only on payer mix but also on modality mix, going towards higher end treatment

Terms & conditions and other disclosures

ANALYST CERTIFICATION

I/We, Siddhant Khandekar, Inter CA, Raunak Thakur, PGDM, Kush Mehta, CA, Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India’s largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. (“associates”), the details in respect of which are available on www.icicibank.com.

 

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

 

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

 

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

 

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

 

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

 

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

 

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

 

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

 

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

 

 

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

 

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

 

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

 

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/ beneficial ownership of one percent or more or other material conflict of interest various companies including the subject company/companies mentioned in this report.

 

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

 

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

 

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

 

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

Read More